Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) FCF Margin (2016 - 2025)

Historic FCF Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 558.18%.

  • Intellia Therapeutics' FCF Margin rose 3870100.0% to 558.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 717.27%, marking a year-over-year increase of 1253600.0%. This contributed to the annual value of 612.78% for FY2024, which is 5121600.0% up from last year.
  • As of Q3 2025, Intellia Therapeutics' FCF Margin stood at 558.18%, which was up 3870100.0% from 701.02% recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' FCF Margin registered a high of 4933.44% during Q4 2023, and its lowest value of 23186.67% during Q3 2021.
  • In the last 5 years, Intellia Therapeutics' FCF Margin had a median value of 701.02% in 2025 and averaged 1610.84%.
  • As far as peak fluctuations go, Intellia Therapeutics' FCF Margin crashed by -230550000bps in 2021, and later surged by 225627900bps in 2022.
  • Over the past 5 years, Intellia Therapeutics' FCF Margin (Quarter) stood at 447.48% in 2021, then tumbled by -54bps to 690.94% in 2022, then surged by 814bps to 4933.44% in 2023, then tumbled by -114bps to 669.38% in 2024, then grew by 17bps to 558.18% in 2025.
  • Its FCF Margin was 558.18% in Q3 2025, compared to 701.02% in Q2 2025 and 900.13% in Q1 2025.